Andere talen Revvity, Inc.

Aandelen

RVTY

US7140461093

Vertraagde tijd Nyse Andere beurzen 21:46:13 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
103,1 ^USD	+2,28%		+2,78%	-5,71%

04:30	REVVITY, INC. : Bernstein is Neutraal over het aandeel	ZM
04:10	REVVITY, INC. : Baird handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Revvity Signals Software's New Synergy Solution Redefines Collaboration between Pharma and Contract Partners	16/04
Revvity Signals Software’s New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners	15/04
Revvity To Hold Earnings Call on Monday, April 29, 2024	04/04
Preliminary Injunction Granted to Enforce Revvity s Rights and Cloud Software Group s Obligations Related to Spotfire Software	03/04
Revvity Says Court Issued Preliminary Injunction Against Cloud Software Group	03/04
Revvity Says Court Issued Preliminary Injunction Against Cloud Software Group	02/04
Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software	02/04
Revvity Files Lawsuit Against Partner Cloud Software Group, Reaffirms 2024 Guidance	20/03
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group	20/03
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	20/03
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication	18/03
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication	18/03
Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research	15/03
Revvity : Notice of Annual Meeting and Proxy Statement 2024	13/03
Revvity Inc Receives a Shareholder Proposal from John Chevedden	13/03
Revvity to Present at Upcoming Investor Conferences	21/02
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions	12/02
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions	12/02
Revvity Insider Sold Shares Worth $3,841,563, According to a Recent SEC Filing	08/02
Revvity Insider Sold Shares Worth $1,613,697, According to a Recent SEC Filing	07/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Revvity, Inc.

Aandelen

RVTY

US7140461093

Andere talen

Filters